Literature DB >> 15135174

Quantification of 1,N6-etheno-2'-deoxyadenosine in human urine by column-switching LC/APCI-MS/MS.

Peter R Hillestrøm1, Anne-Mette Hoberg, Allan Weimann, Henrik E Poulsen.   

Abstract

1,N6-etheno-2'-deoxyadenosine (epsilondA) is one of several promutagenic DNA modifications arising from cellular oxidative metabolism. It is believed that these background DNA lesions may contribute to various diseases, such as cancer. Therefore, human biomonitoring of epsilondA in urine could be a potential marker for oxidative stress-related DNA damage. Existing methods for quantifying urinary epsilondA use 32P postlabeling. We have developed a nonradioactive, fast, and easier method based on column-switching liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry (LC/APCI-MS/MS) in the positive mode. Differences in column temperatures were used to influence analyte retention and sample focusing. With multiple reaction monitoring (MRM) mode the afforded limit of detection was about 0.7 pM when starting with 3 ml of urine. The urinary excretion rates of epsilondA from 28 nonsmoking and 5 smoking men were 10.0-99.6 pmol/24 h, and did not correlate with body weight, age, or plasma vitamin C concentration. The 5 smokers excreted 30.5 +/-8.5 and the 28 nonsmokers excreted 38.6 +/- 2.4 pmol epsilondA per 24 h, p=.37 (mean +/- SEM). The demonstrated level of performance suggests the future applicability of this method to studies of cancer and other diseases related to oxidative stress in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135174     DOI: 10.1016/j.freeradbiomed.2004.02.068

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  9 in total

Review 1.  Mass spectrometry of structurally modified DNA.

Authors:  Natalia Tretyakova; Peter W Villalta; Srikanth Kotapati
Journal:  Chem Rev       Date:  2013-02-26       Impact factor: 60.622

2.  Impairment of aldehyde dehydrogenase 2 increases accumulation of acetaldehyde-derived DNA damage in the esophagus after ethanol ingestion.

Authors:  Yoshiyuki Yukawa; Shinya Ohashi; Yusuke Amanuma; Yukie Nakai; Mihoko Tsurumaki; Osamu Kikuchi; Shin'ichi Miyamoto; Tsunehiro Oyama; Toshihiro Kawamoto; Tsutomu Chiba; Tomonari Matsuda; Manabu Muto
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

3.  Quantification of urinary etheno-DNA adducts by column-switching LC/APCI-MS/MS.

Authors:  Peter R Hillestrøm; Allan Weimann; Henrik E Poulsen
Journal:  J Am Soc Mass Spectrom       Date:  2006-02-28       Impact factor: 3.109

Review 4.  Quantitation of DNA adducts by stable isotope dilution mass spectrometry.

Authors:  Natalia Tretyakova; Melissa Goggin; Dewakar Sangaraju; Gregory Janis
Journal:  Chem Res Toxicol       Date:  2012-08-28       Impact factor: 3.739

Review 5.  Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair.

Authors:  Helmut Bartsch; Jagadeesan Nair
Journal:  Langenbecks Arch Surg       Date:  2006-08-15       Impact factor: 3.445

6.  Biomarkers of nucleic acid oxidation - A summary state-of-the-art.

Authors:  Mu-Rong Chao; Mark D Evans; Chiung-Wen Hu; Yunhee Ji; Peter Møller; Pavel Rossner; Marcus S Cooke
Journal:  Redox Biol       Date:  2021-01-28       Impact factor: 11.799

7.  Ultrasensitive UPLC-MS-MS method for the quantitation of etheno-DNA adducts in human urine.

Authors:  Shiwei Cui; Haibin Li; Shaojia Wang; Xiao Jiang; Shusheng Zhang; Rongjie Zhang; Xin Sun
Journal:  Int J Environ Res Public Health       Date:  2014-10-21       Impact factor: 3.390

8.  Current literature in mass spectrometry.

Authors: 
Journal:  J Mass Spectrom       Date:  2004-11       Impact factor: 1.982

9.  Sources of extracellular, oxidatively-modified DNA lesions: implications for their measurement in urine.

Authors:  Marcus S Cooke; Paul T Henderson; Mark D Evans
Journal:  J Clin Biochem Nutr       Date:  2009-10-28       Impact factor: 3.114

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.